Zacks.com on MSN

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.

Vertex Pharmaceuticals’ Suzetrigine Study: A New Frontier in Pain Management

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.